Ph+ ALL in 2026: Optimizing TKI Selection, Combination Strategies, and Rethinking Transplant

This session, led by Dr. Michal Bar-Natan, explores evolving strategies in the management of Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph+ ALL) in 2026, with a focus on optimizing tyrosine kinase inhibitor (TKI) selection and sequencing. Recent data highlighting the efficacy of next-generation TKIs, including ponatinib and asciminib, in both frontline and relapsed settings will be discussed. The session will also examine emerging combination approaches integrating TKIs with blinatumomab and other immunotherapies to deepen molecular responses and potentially minimize chemotherapy exposure. Additionally, new evidence challenging the routine use of allogeneic stem cell transplant in first remission—particularly in patients achieving sustained MRD negativity—will be reviewed. Practical considerations for tailoring therapy based on mutation profile, tolerability, and long-term outcomes will be emphasized.